-
Article
Open AccessCorrection: Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer’s disease
-
Article
Open AccessRare variants in IFFO1, DTNB, NLRC3 and SLC22A10 associate with Alzheimer’s disease CSF profile of neuronal injury and inflammation
Alzheimer’s disease (AD) biomarkers represent several neurodegenerative processes, such as synaptic dysfunction, neuronal inflammation and injury, as well as amyloid pathology. We performed an exome-wide rare ...
-
Article
Open AccessCerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer’s disease
Increased total tau (t-tau) in cerebrospinal fluid (CSF) is a key characteristic of Alzheimer’s disease (AD) and is considered to result from neurodegeneration. T-tau levels, however, can be increased in very ...
-
Article
Open AccessGenome-wide association study of Alzheimer’s disease CSF biomarkers in the EMIF-AD Multimodal Biomarker Discovery dataset
Alzheimer’s disease (AD) is the most prevalent neurodegenerative disorder and the most common form of dementia in the elderly. Susceptibility to AD is considerably determined by genetic factors which hitherto ...
-
Article
Open AccessAPOE ε4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer’s disease
Aggregation of amyloid β into plaques in the brain is one of the earliest pathological events in Alzheimer’s disease (AD). The exact pathophysiology leading to dementia is still uncertain, but the apolipoprote...
-
Article
Biomarkers voor de ziekte van Alzheimer: relaties met vasculaire factoren, neurodegeneratie en cognitie in de predementiële fasen
Hoewel biomarkers het inzicht in de ziekte van Alzheimer (AD) hebben vergroot, bestaat er nog veel onduidelijkheid en is er nog geen effectieve behandeling beschikbaar voor deze complexe aandoening. Vanuit de ...
-
Article
Open AccessMRI predictors of amyloid pathology: results from the EMIF-AD Multimodal Biomarker Discovery study
With the shift of research focus towards the pre-dementia stage of Alzheimer’s disease (AD), there is an urgent need for reliable, non-invasive biomarkers to predict amyloid pathology. The aim of this study wa...
-
Article
Open AccessThe EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristics
There is an urgent need for novel, noninvasive biomarkers to diagnose Alzheimer’s disease (AD) in the predementia stages and to predict the rate of decline. Therefore, we set up the European Medical Informatio...
-
Article
Open AccessCorrection to: Cerebrovascular and amyloid pathology in predementia stages: the relationship with neurodegeneration and cognitive decline
Upon publication of this article [1], it was noticed that there were some inconsistencies in Tables 1, 2 and 3. Some of the superscript letters were incorrectly assigned. Please see below the correct tables:
-
Article
Open AccessCerebrovascular and amyloid pathology in predementia stages: the relationship with neurodegeneration and cognitive decline
Cerebrovascular disease (CVD) and amyloid-β (Aβ) often coexist, but their influence on neurodegeneration and cognition in predementia stages remains unclear. We investigated the association between CVD and Aβ ...